Use of daratumumab in a patient with proliferative glomerulonephritis with monoclonal immunoglobulin deposition: A case report. Issue 1 (February 2023)

• Record Type: Journal Article
• Authors: Doddi, Akshith; Ibrahim, Dalia; Shawwa, Khaled
• Is Part Of: Journal of onco-nephrology. Volume 7:Issue 1(2023)
• Page Start: 42
• Page End: 45
• Publication Date: 2023-02
• Subjects: PGNMID -- daratumumab -- MGRS; Nephrology -- Periodicals; Kidneys -- Cancer -- Periodicals; Kidneys -- Tumors -- Periodicals; 616.61
• DOI: 10.1177/23993693221129293
• Languages: English
• ISSNs: 2399-3693

Abstract

Monoclonal gammopathy of renal significance (MGRS) is a pathogenic entity associated with significant morbidity, mainly end stage kidney disease. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), a type of MGRS, is a specific disease resulting from the deposition of a monoclonal immunoglobulin leading to kidney damage. While PGNMID has been recognized to lead to end-stage kidney disease, until recently there was no evidence to guide treatment. Here, we report a case of a patient with PGNMID who responded well to daratumumab.